Course of pregnancy and lactation in patients with rheumatic disorders and pharmacological treatment of these disorders might be risky. The risk is a consequence of the disease, treatment of the mother before conception, during pregnancy and lactation. Treatment of the father just in the period of time shortly before conception can also be risky. The choice of the treatment of rheumatic disorders in pregnancy and lactation is given mainly by the character of the disease, by its usual course during pregnancy, by the activity, eventually by the affection of internal organs and by the occurrence of intercurrent disease of the woman, by the age of the women, and so on. That is the reason of the different approaches to the treatment of rheumatic disorders. Low levels of glucocorticoids, sulfasalazine andantimalarials are safe.Treatment with gold, azathioprine andcyclosporine A is not eligible during pregnancy, but in some exceptional cases can be assumed. Treatment with methotrexate, penicillamine, leflunomide and cyclophosphamide is strictly contraindicated. It is necessary to ensure effective contraception during the treatment and to discontinue these drugs before conception is planned. During the cyclophosphamide treatment it is also necessary to protect the ovarian follicles before the conception to avoid irreversible amenorrhoea. For this purpose hormonal contraception or cryopreservation of ovarian follicles can be used.

        Key words: rheumatic disorders, pregnancy, lactation, pharmacological treatment